- Home
- PULM
PULM
Pulmatrix Inc.
as 06-20-2025 3:40pm EST
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 33.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 34.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.78 - $10.40 | Next Earning Date: | 08-12-2025 |
| Revenue: | $1,921,000 | Revenue Growth: | -83.56% |
| Revenue Growth (this year): | -8.47% | Revenue Growth (next year): | 134.88% |
Latest Pulmatrix Inc. News
PULM Breaking Stock News: Dive into PULM Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
PR Newswire
3 months ago
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
GlobeNewswire
5 months ago
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain
PR Newswire
7 months ago
Pulmatrix and Cullgen Announce Proposed Merger
Simply Wall St.
7 months ago
Pulmatrix Third Quarter 2024 Earnings: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)
PR Newswire
7 months ago
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Simply Wall St.
10 months ago
Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)
PR Newswire
10 months ago
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Compare PULM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PULM Pulmatrix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.